Veeva Vault PromoMats selected by Roche for Digital Asset Management and Content

MADRID–(BUSINESS WIRE)–2018 Veeva European Commercial Medical SummitVeeva
(NYSE:VEEV) today announced that Roche
(SWX:ROG) is adopting Veeva
Vault PromoMats
as their global content and digital asset management
(DAM) solution.

“We are proud to partner with Roche on this important initiative to
speed time to market of their commercial and medical content,” said John
Chinnici, vice president of commercial content at Veeva. “Vault
PromoMats gives the life sciences industry a single solution to easily
create and distribute content with integrated capabilities to manage
rich digital assets.”

Vault PromoMats is the first and only application that combines digital
asset management with medical, legal, and regulatory review. Companies
can eliminate the need to move, duplicate, and manage content and
digital assets across multiple systems for improved visibility, control,
and compliance throughout the digital supply chain.

In other news, Veeva introduced Veeva Vault Digital Publishing, a new
digital asset management capability in Vault PromoMats and Vault
for brand marketing teams to publish and withdraw approved
assets from a central location to any digital channel for faster and
easier publishing. Read today’s press
to learn more.

To learn more about how Roche and Veeva are working together on
transforming digital content management, visit:

Additional Information

For more on Veeva Vault PromoMats, visit:

Connect with Veeva on LinkedIn:

Follow @veeva_eu on Twitter:

Like Veeva on Facebook:

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 675 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices throughout
North America, Europe, Asia, and Latin America. For more information,

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended July 31, 2018. This is available on the
company’s website at
under the Investors section and on the SEC’s website at
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to